Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease

PURPOSE: To describe the clinical course of advanced juxtapapillary retinal capillary hemangioblastomas (RCH) associated with von Hippel-Lindau (VHL) disease treated with systemic sunitinib malate, an agent that inhibits both anti-vascular endothelial growth factor and anti-platelet-derived growth f...

Full description

Saved in:
Bibliographic Details
Published in:Ophthalmol Retina
Main Authors: Knickelbein, Jared E., Jacobs-El, Naima, Wong, Wai T., Wiley, Henry E., Cukras, Catherine A., Meyerle, Catherine B., Chew, Emily Y.
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5490440/
https://ncbi.nlm.nih.gov/pubmed/28670632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oret.2016.10.007
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items